AnaptysBio, Inc.

LSE:0HFQ Stock Report

Market Cap: US$733.3m

AnaptysBio Valuation

Is 0HFQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HFQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0HFQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0HFQ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HFQ?

Key metric: As 0HFQ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0HFQ. This is calculated by dividing 0HFQ's market cap by their current revenue.
What is 0HFQ's PS Ratio?
PS Ratio12.8x
SalesUS$57.17m
Market CapUS$733.33m

Price to Sales Ratio vs Peers

How does 0HFQ's PS Ratio compare to its peers?

The above table shows the PS ratio for 0HFQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.7x
OXB Oxford Biomedica
4.6x21.0%UK£447.3m
GNS Genus
1.7x3.5%UK£1.1b
BVXP Bioventix
14.4xn/aUK£195.7m
ONC Oncimmune Holdings
14.1x105.1%UK£17.2m
0HFQ AnaptysBio
12.8x10.6%US$733.3m

Price-To-Sales vs Peers: 0HFQ is expensive based on its Price-To-Sales Ratio (12.8x) compared to the peer average (8.7x).

Price to Sales Ratio vs Industry

How does 0HFQ's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.39b
OXB Oxford Biomedica
4.6x21.0%US$561.36m
TRX Tissue Regenix Group
1.6x15.1%US$50.96m
VRCI Verici Dx
2.4x78.8%US$10.27m
0HFQ 12.8xIndustry Avg. 8.0xNo. of Companies8PS020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0HFQ is expensive based on its Price-To-Sales Ratio (12.8x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0HFQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HFQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.8x
Fair PS Ratio0.7x

Price-To-Sales vs Fair Ratio: 0HFQ is expensive based on its Price-To-Sales Ratio (12.8x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HFQ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$23.98
US$54.36
+126.7%
32.7%US$90.00US$30.00n/a11
Nov ’25US$22.22
US$55.64
+150.4%
33.0%US$90.00US$30.00n/a11
Oct ’25US$33.75
US$54.27
+60.8%
32.0%US$80.00US$23.00n/a11
Sep ’25US$37.88
US$54.27
+43.3%
32.0%US$80.00US$23.00n/a11
Aug ’25US$34.35
US$48.90
+42.4%
36.7%US$80.00US$20.00n/a10
Jul ’25US$24.69
US$43.78
+77.3%
41.3%US$80.00US$20.00n/a9
Jun ’25US$24.69
US$43.78
+77.3%
41.3%US$80.00US$20.00n/a9
May ’25US$25.07
US$43.50
+73.5%
40.2%US$80.00US$20.00n/a10
Apr ’25US$22.32
US$41.50
+85.9%
45.6%US$80.00US$20.00n/a8
Mar ’25US$25.44
US$40.00
+57.2%
50.0%US$80.00US$20.00n/a8
Feb ’25US$23.42
US$27.00
+15.3%
34.4%US$44.00US$20.00n/a5
Jan ’25n/a
US$27.00
0%
34.4%US$44.00US$20.00n/a5
Dec ’24n/a
US$27.00
0%
34.4%US$44.00US$20.00n/a5
Nov ’24US$16.13
US$26.80
+66.1%
37.3%US$45.00US$18.00US$22.225
Oct ’24n/a
US$29.80
0%
27.9%US$45.00US$20.00US$33.755
Sep ’24US$20.10
US$29.80
+48.3%
27.9%US$45.00US$20.00US$37.885
Aug ’24US$20.49
US$32.00
+56.2%
20.4%US$45.00US$28.00US$34.355
Jul ’24US$20.22
US$32.00
+58.3%
20.4%US$45.00US$28.00US$24.695
Jun ’24US$18.81
US$30.33
+61.3%
23.2%US$45.00US$22.00US$24.696
May ’24US$20.97
US$31.33
+49.4%
18.4%US$44.00US$28.00US$25.076
Apr ’24n/a
US$31.50
0%
18.3%US$44.00US$28.00US$22.326
Mar ’24n/a
US$31.83
0%
17.6%US$44.00US$28.00US$25.446
Feb ’24n/a
US$31.29
0%
19.9%US$44.00US$23.00US$23.427
Jan ’24n/a
US$32.50
0%
18.8%US$44.00US$23.00n/a8
Dec ’23n/a
US$32.50
0%
18.8%US$44.00US$23.00n/a8
Nov ’23US$28.65
US$29.13
+1.7%
23.9%US$44.00US$21.00US$16.138

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$749.75

7D

0.4%

1Y

-5.8%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

2.4%

1Y

12.5%